Myovant Sciences Ltd. reported earnings results for the second quarter and six months ended September 30, 2022. For the second quarter, the company reported revenue was USD 104.82 million compared to USD 77.9 million a year ago. Net loss was USD 45.62 million compared to USD 21.59 million a year ago. Basic loss per share from continuing operations was USD 0.47 compared to USD 0.23 a year ago.
For the six months, revenue was USD 221.32 million compared to USD 118.97 million a year ago. Net loss was USD 66.86 million compared to USD 83.25 million a year ago. Basic loss per share from continuing operations was USD 0.7 compared to USD 0.9 a year ago.